An exposure‐response analysis of ponesimod clinical efficacy in a randomized phase III study in patients with relapsing multiple sclerosis

The efficacy of ponesimod and teriflunomide for the treatment of relapsing multiple sclerosis (MS) was compared in a randomized phase III trial. This study explores the exposure‐response (E‐R) relationships of efficacy end points (annualized relapse rate [ARR] and combined unique active lesions [CUA...

Descripción completa

Detalles Bibliográficos
Autores principales: Valenzuela, Belén, Olsson Gisleskog, Per, Poggesi, Italo, Sidorenko, Tatiana, Burcklen, Michel, Kracker, Hilke, Pérez‐Ruixo, Juan Jose
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574745/
https://www.ncbi.nlm.nih.gov/pubmed/36047474
http://dx.doi.org/10.1002/psp4.12778

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574745/
https://www.ncbi.nlm.nih.gov/pubmed/36047474
http://dx.doi.org/10.1002/psp4.12778

Ejemplares similares